Brevan Howard Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Brevan Howard Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.79M	Buy	143,997 +73,912	+105%	+$992K	0.02%	602
2025 Q4	$883K	Buy	70,085 +53,006	+310%	+$606K	0.01%	822
2025 Q3	$171K	Buy	+17,079	New	+$153K	﹤0.01%	1782
2025 Q1	–	Sell	-13,571	Closed	-$107K	–	1141
2024 Q4	$107K	Buy	+13,571	New	+$114K	﹤0.01%	963
2024 Q2	–	Sell	-12,817	Closed	-$77.7K	–	1045
2024 Q1	$77.7K	Sell	12,817 -35,887	-74%	-$202K	﹤0.01%	914
2023 Q4	$296K	Buy	+48,704	New	+$217K	﹤0.01%	716

Other funds holding AMRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Brevan Howard Capital Management's AMRX Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Amneal Pharmaceuticals (AMRX) stake by 105% in Q1 2026, buying an estimated $992K and bringing the position to 143,997 shares worth $1.79M. The position accounts for 0.02% of the portfolio, ranked #602.

Brevan Howard Capital Management first reported a position in AMRX in Q4 2023 and has held it in 6 quarters since. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Brevan Howard Capital Management held 143,997 shares of Amneal Pharmaceuticals worth $1.79M as of Q1 2026.
Brevan Howard Capital Management bought 73,912 Amneal Pharmaceuticals shares in Q1 2026, an estimated $992K.
Amneal Pharmaceuticals made up 0.02% of Brevan Howard Capital Management's portfolio in Q1 2026, its #602 holding.
Brevan Howard Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.